Scientific research can be confusing and overwhelming. We not only fund research, but we also help you understand RET-positive research and what it means for current treatment options and future therapies.
Research
Research Funding
We fund and facilitate research for treatments so that more RET-positive lung cancer patients will live fuller, healthier lives.
Our researchers are investigating resistance to currently available targeted therapies, including:
- Identifying new, more effective combination therapies for RET-inhibitor resistant disease
- Testing innovative adaptive T cell therapies such as TCR immunotherapies for RET cancers
- Generating new RET cancer preclinical models, including cell likes and patient-derived xenograft mouse models
We also work closely with the offices of leading cancer research institutions to assist them in securing grant funding for continued RET-positive research.
Since our inception in 2021, we have awarded more than $1 million in RET-positive cancer research grants and facilitated an additional $1 million in research funding.
Webinars
We host webinars that bring together members of the scientific community with patients and caregivers to explain the latest research findings.
2025 RET Research Update
2024 RET Research Update
More About Research
Continuing a RET Inhibitor With Chemotherapy After Progression May Improve Outcomes For RET Lung Cancer Patients
Continuing a RET Inhibitor With Chemotherapy After Progression May Improve Outcomes For RET Lung Cancer Patients
Read More
New FOXM1 T cell therapies that can target RET tumors
New FOXM1 T cell therapies that can target RET tumors
Read More
What the New NCCN Guidelines Mean for RET+ Lung Cancer
What the New NCCN Guidelines Mean for RET+ Lung Cancer
Read More
RET Highlights Presented at the 2026 American Society of Clinical Oncology (ASCO)
RET Highlights Presented at the 2026 American Society of Clinical Oncology (ASCO)
Read More
ASCO 2026: Selpercatinib Shows Strong Results in Early-Stage RET+ Lung Cancer
ASCO 2026: Selpercatinib Shows Strong Results in Early-Stage RET+ Lung Cancer
Read More
New AACR 2026 Findings on TP53 Co-Mutations and RET Fusion Partners in RET+ NSCLC
New AACR 2026 Findings on TP53 Co-Mutations and RET Fusion Partners in RET+ NSCLC
Read More
RET Cancer Research Takes Center Stage at ASCO, May 2026
RET Cancer Research Takes Center Stage at ASCO, May 2026
Read More
Don’t Miss Together Separately, presented by LCRF and the Susan Wojcicki Foundation on May 14th, 2026
Don’t Miss Together Separately, presented by LCRF and the Susan Wojcicki Foundation on May 14th, 2026
Read More
BioNTech’s BNT116 mRNA cancer vaccine trial has opened a new RET cohort
BioNTech’s BNT116 mRNA cancer vaccine trial has opened a new RET cohort
Read MoreMore About Research
Continuing a RET Inhibitor With Chemotherapy After Progression May Improve Outcomes For RET Lung Cancer Patients
Continuing a RET Inhibitor With Chemotherapy After Progression May Improve Outcomes For RET Lung Cancer Patients
Read MoreNew FOXM1 T cell therapies that can target RET tumors
New FOXM1 T cell therapies that can target RET tumors
Read MoreWhat the New NCCN Guidelines Mean for RET+ Lung Cancer
What the New NCCN Guidelines Mean for RET+ Lung Cancer
Read MoreRET Highlights Presented at the 2026 American Society of Clinical Oncology (ASCO)
RET Highlights Presented at the 2026 American Society of Clinical Oncology (ASCO)
Read MoreASCO 2026: Selpercatinib Shows Strong Results in Early-Stage RET+ Lung Cancer
ASCO 2026: Selpercatinib Shows Strong Results in Early-Stage RET+ Lung Cancer
Read MoreNew AACR 2026 Findings on TP53 Co-Mutations and RET Fusion Partners in RET+ NSCLC
New AACR 2026 Findings on TP53 Co-Mutations and RET Fusion Partners in RET+ NSCLC
Read MoreRET Cancer Research Takes Center Stage at ASCO, May 2026
